Programme

SPEAKERS

Pan-Chyr Yang

AFFILIATION:

National Taiwan University College of Medicine, Taiwan, ROC

POSITION TITLE:

Past President of National Taiwan University
Academician, Academia Sinica
Chair Professor of Internal Medicine

EDUCATION/TRAINING:

National Taiwan University, College of Medicine                                         M.D.        1979        Medicine
National Taiwan University, Graduate Institute of Clinical Medicine   Ph.D.       1990        Medicine

 

HONORS:

2020                The Phi Tau Phi Outstanding Achievement Award
2015                Fellow, National Academy of Inventors (NAI)
2008                Academician, The World Academy of Sciences
2007-2008       National Chair Professor, Ministry of Education, Taiwan R.O.C.
2006                Chair Professor, National Taiwan University
2006                Distinguished Professor, National Taiwan University
2006                Academician, Academia Sinica, Taiwan, ROC
2003                10th TECH Technology Award
2002                Academic Award, Ministry of Education, R.O.C.
2001-2006       Outstanding Scholar Award, Foundation for the
1999, 2012      Advancement of Outstanding Scholarship Distinguished Teacher Award, National Taiwan University
1997                The 7th Annual Wang Ming-Ning Award
1994-1999       Outstanding Research Award, National Science Council
1993, 1997      Distinguished Clinical Teacher Award, NTUCMAF
1993                Ten Outstanding Youth Award, R.O.C

 

 

RESEARCH INTERESTS:

Dr. Yang is Chair Professor of National Taiwan University College of Medicine. He was the former President of National Taiwan University. His major research interests are lung cancer genomics and precision lung cancer therapy. He was elected as member of Academia Sinica in 2006 and the World Academic of Science in 2008 as well as the National Academy of Inventors of USA in 2015 because of his contributions in leading the translational research in precision cancer medicine and the implementation of lung cancer screening in never smoker, which significantly improved the survival of lung cancer patients in Taiwan. Their research group identified the proteogenomics signatures of pathogenesis and progression of never smoker lung cancer in the East Asian population. They successfully established new platforms of theranostic applications of aptamer and smart targeting of cancer stem cell and tumor microenvironment that may provide a new strategy to improve treatment outcomes of lung cancer patients.

 

PUBLICATIONS:

List of published work in Google Scholar:
https://scholar.google.com/citations?hl=zh-TW&user=uhM7QZ8AAAAJ